Pathogenic Cav3.2 channel mutation in a child with primary generalized epilepsy
Ivana A Souza1, Maria A Gandini1, Fang-Xiong Zhang1
1Department of Physiology and Pharmacology, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada.
Two CACNA1H gene variants were studied in a child with generalized epilepsy. One variant showed a gain-of-function effect, suggesting a role in epilepsy pathogenesis.
Area of Science:
- Neurogenetics
- Ion channel research
- Epilepsy genetics
Background:
- Generalized epilepsy is a neurological disorder with diverse genetic underpinnings.
- The CACNA1H gene encodes a T-type calcium channel subunit (Cav3.2), implicated in neuronal excitability.
- Understanding the genetic variants associated with epilepsy is crucial for diagnosis and treatment.
Observation:
- A 6-year-old child presented with febrile and unprovoked seizures.
- Two paternally inherited missense variants in the CACNA1H gene were identified in the patient.
- These variants were expressed in vitro using human recombinant Cav3.2 channels.
Findings:
- Electrophysiological recordings revealed that the c.3844C>T (p.R1282W) variant resulted in a significant increase in current density.
- This gain-of-function phenotype suggests pathogenicity.
- The co-inherited c.5294C>T (p.A1765V) variant exhibited a benign functional profile.
Implications:
- The p.R1282W variant in CACNA1H may contribute to generalized epilepsy through a gain-of-function mechanism.
- This finding highlights the importance of Cav3.2 channels in epilepsy pathogenesis.
- Further research into CACNA1H variants could lead to novel therapeutic strategies for epilepsy.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...


